Therapeutic drug monitoring in peritoneal dialysis: A case of nontuberculous mycobacterium catheter‐related infection treated with amikacin
Sanae Kojya, Hideo Shiohira, Yoshitsugu Sunagawa and 6 more
Clinical Case Reports · 2020
doi:10.1002/ccr3.2774 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Abstract The pharmacokinetics of amikacin makes it difficult to predict the appropriate dosing to avoid harmful side effects in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). The implementation of therapeutic drug monitoring may be useful in controlling amikacin serum concentrations in patients receiving CAPD.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.